There is limited research on the combined use of esketamine and alfentanil for anesthesia during facial laser treatment in pediatric patients, and the effective dosage of esketamine for inhibiting body movement remains unclear. We explore the effective dose of esketamine combined with alfentanil for the inhibition of body movement during facial laser treatment in pediatric patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
40
esketamine will be given intravenously
half effective dose of inhibition of body movement
Time frame: from injection of esketamine to start of laser treatment, in an average of 5 minutes
number of patients with agitation during awake
Time frame: from end of injection of esketamine to 30 minutes after laser treatment, in an average of 60 minutes
number of patients with dizzy during awake
Time frame: from end of injection of esketamine to 30 minutes after laser treatment, in an average of 60 minutes
number of patients with nausea and vomiting during awake
Time frame: from end of injection of esketamine to 30 minutes after laser treatment, in an average of 60 minutes
number of patients with apnea during awake
Time frame: from end of injection of esketamine to 30 minutes after laser treatment, in an average of 60 minutes
satisfaction score of the parents to the anesthesia
The satisfaction of the parents to the anesthesia will be assessed by visual analogue scale, of which 0 is for extremely not satisfied, 10 is for extremely satisfied
Time frame: from end of laser treatment to discharge from the outpatient unit, in an average of 60 minutes
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.